Chikungunya virus vaccine candidate incorporating synergistic mutations is attenuated and protects against virulent virus challenge

BackgroundChikungunya virus (CHIKV) is an arbovirus that periodically reemerges to cause large epidemics of arthritic disease. While the robust immunity elicited by live-attenuated virus (LAV) vaccine candidates makes them attractive, CHIKV vaccine development has been hampered by a high threshold for acceptable adverse events. MethodsWe evaluated the vaccine potential of a recently described LAV, SKE, that exhibits diminished replication in skeletal muscle cells due to insertion of target sequences for skeletal muscle-specific miR-206. We also evaluated whether these target sequences could augment safety of a LAV encoding a previously described attenuating mutation, E2 G82R, which on its own was too reactogenic in clinical trials. Attenuation of viruses containing these mutations was compared with a double mutant, SKE G82R. ResultsSKE was attenuated in both immunodeficient and immunocompetent mice and induced a robust neutralizing antibody response, indicating its vaccine potential. However, only SKE G82R elicited diminished swelling in immunocompetent mice at early time points post-inoculation, indicating that these mutations synergistically enhance safety of the vaccine candidate. ConclusionsThese data suggest that restriction of LAV replication in skeletal muscle enhances tolerability of reactogenic vaccine candidates and may improve the rational design of CHIKV vaccines.